Education
About Us
Working with TipRanks
Follow Us
Sanara MedTech (SMTI)
NASDAQ:SMTI
SMTI Stock Chart & Stats
$29.52
$0.13(0.40%)
At close: 4:00 PM EST
$29.52
$0.13(0.40%)
Day’s Range― - ―
52-Week Range$18.29 - $35.95
Previous CloseN/A
Volume5.72K
Average Volume (3M)61.65K
Market Cap
$185.33M
Enterprise Value$217.78M
Total Cash (Recent Filing)$14.94M
Total Debt (Recent Filing)$47.39M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 24, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.40
Shares Outstanding8,935,657
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)7.15
Price to Sales (P/S)3.25
P/FCF Ratio-1.11K
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue2.14
Enterprise Value/Gross Profit2.32
Enterprise Value/Ebitda-8.13
Forecast
1Y Price Target
$36.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.48
Revenue Forecast (FY)$116.85M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion And PartnershipsExpansion of the sales and distribution network and the strategic alliance with Biomimetic Innovations broadens commercial reach and supports faster roll-out of OsStic and BIASURGE across hospital systems.
Regulatory Designation And Clinical DifferentiationBreakthrough Device designation for OsStic combined with preclinical results showing much stronger bonding than traditional bone cements underscores clear clinical differentiation that could drive surgeon interest.
Strategic ContractContract with Vizient expands access to BIASURGE through contracted pricing and pre-negotiated terms, supporting wider hospital adoption and more predictable revenue channels.
Bears Say
Balance Sheet LeverageReported cash balances that are smaller than long-term debt indicate elevated leverage, which could limit the company's ability to withstand revenue variability or pursue opportunistic investments.
Growth Funding ConstraintsHigh long-term debt relative to available cash may force prioritization of debt servicing over commercial expansion and product development, potentially slowing planned growth initiatives.
Liquidity And Refinancing RiskA modest cash position alongside significant long-term debt raises the risk of needing additional financing, which could increase interest costs or lead to shareholder dilution if capital is raised.
Sanara MedTech News
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $18.29 and its highest was $35.95 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $185.33M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is Mar 24, 2026 which is in 13 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on Nov 12, 2025. The company reported -$3.4 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$3.185.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is 0.11.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 8,935,657 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of -$3.4 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went down -24.715%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanara MedTech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (21.95% Upside)
$36.00 (21.95% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 70%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.65%
12-Months-Change
Fundamentals
Return on Equity
-27.19%
Trailing 12-Months
Asset Growth
-19.71%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.
SMTI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Sanara MedTech demonstrated strong revenue growth and improved profitability, driven by its core surgical business and strategic network expansion. However, the discontinuation of Tissue Health Plus and increased operating expenses pose challenges.View all SMTI earnings summariesSMTI Stock 12 Month Forecast
Average Price Target
$36.00
▲(21.95% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sharps Technology, Inc.
―
Ownership Overview
41.76% Insiders
3.00% Mutual Funds
1.63% Other Institutional Investors
50.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---